A24 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE I: Td139, A Novel Inhaled Galectin-3 Inhibitor For The Treatment Of Idiopathic Pulmonary Fibrosis (ipf). Results From The First In (ipf) Patients Study

A24 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE I: Td139, A Novel Inhaled Galectin-3 Inhibitor For The Treatment Of Idiopathic Pulmonary Fibrosis (ipf). Results From The First In (ipf) Patients Study

Galectin-3 is a pro-fibrotic ß-galactoside binding lectin highly expressed in fibrotic lung and macrophages from IPF patients. A randomized, double-blind, multicenter, placebo-controlled, phase IIa study to assess the safety, tolerability, PK (pharmacokinetics) and PD (pharmacodynamics) of TD139 in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Hirani, N, Mackinnon, A, Nicol, L, Walker, J, d, P, Schambye, H, Pederson, A, Nilsson, U, Leffler, H, Thomas, T, Francombe, D, Simpson, J, Gibbons, M, Maher, T M
Format: Artikel
Sprache:eng
Schlagworte:
Drug dosages
Pulmonary fibrosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Galectin-3 is a pro-fibrotic ß-galactoside binding lectin highly expressed in fibrotic lung and macrophages from IPF patients. A randomized, double-blind, multicenter, placebo-controlled, phase IIa study to assess the safety, tolerability, PK (pharmacokinetics) and PD (pharmacodynamics) of TD139 in 24 IPF patients.
ISSN:1073-449X
1535-4970